Combination Therapy with Dendritic Cells and Lenalidomide is an Effective Approach to Enhance Antitumor Immunity in a Mouse Colon Cancer Model

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 May 3

PMID 28460478

Citations 25

Authors

Manh-Cuong Vo

Thanh-Nhan Nguyen-Pham

Hyun-Ju Lee

Thangaraj Jaya Lakshmi

Seoyun Yang

Sung-Hoon Jung

Hyeoung-Joon Kim

Je-Jung Lee

Affiliations

Soon will be listed here.

Abstract

In this study, we investigated efficacy of lenalidomide in combination with tumor antigen-loaded dendritic cells (DCs) in murine colon cancer model. MC-38 cell lines were injected subcutaneously to establish colon cancer-bearing mice. After tumor growth, lenalidomide (50 mg/kg/day) was injected intraperitoneally on 3 consecutive days in combination with tumor antigen-loaded DC vaccination on days 8, 12, 16, and 20. The tumor antigen-loaded DCs plus lenalidomide combination treatment exhibited a significant inhibition of tumor growth compared with the other groups. These effects were associated with a reduction in immune suppressor cells, such as myeloid-derived suppressor cells and regulatory T cells, with the induction of immune effector cells, such as natural killer cells, CD4+ T cells and CD8+ T cells in spleen, and with the activation of cytotoxic T lymphocytes and NK cells. This study suggests that a combination of tumor antigen-loaded DC vaccination and lenalidomide synergistically enhanced antitumor immune response in the murine colon cancer model, by inhibiting the generation of immune suppressive cells and recovery of effector cells, and demonstrated superior polarization of Th1/Th2 balance in favor of Th1 immune response. This combination approach with DCs and lenalidomide may provide a new therapeutic option to improve the treatment of colon cancer.

Citing Articles

Hypofractionated radiotherapy combined with lenalidomide improves systemic antitumor activity in mouse solid tumor models.

Onyshchenko K, Luo R, Rao X, Zhang X, Gaedicke S, Grosu A Theranostics. 2024; 14(6):2573-2588.

PMID: 38646638 PMC: 11024858. DOI: 10.7150/thno.88864.

Dendritic Cell-Based Immunotherapy: The Importance of Dendritic Cell Migration.

Song M, Nam J, Noh K, Lim D J Immunol Res. 2024; 2024:7827246.

PMID: 38628676 PMC: 11019573. DOI: 10.1155/2024/7827246.

Combination of pioglitazone and dendritic cell to optimize efficacy of immune cell therapy in CT26 tumor models.

Tokhanbigli S, Alavifard H, Aghdaei H, Zali M, Baghaei K Bioimpacts. 2023; 13(4):333-346.

PMID: 37645031 PMC: 10460770. DOI: 10.34172/bi.2022.24209.

The effects of dendritic cell-based vaccines in the tumor microenvironment: Impact on myeloid-derived suppressor cells.

Sanchez-Leon M, Jimenez-Cortegana C, Cabrera G, Vermeulen E, de la Cruz-Merino L, Sanchez-Margalet V Front Immunol. 2022; 13:1050484.

PMID: 36458011 PMC: 9706090. DOI: 10.3389/fimmu.2022.1050484.

Biomimetic and Materials-Potentiated Cell Engineering for Cancer Immunotherapy.

Zhang T, Yang Y, Huang L, Liu Y, Chong G, Yin W Pharmaceutics. 2022; 14(4).

PMID: 35456568 PMC: 9024915. DOI: 10.3390/pharmaceutics14040734.

References

List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E . Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006; 355(14):1456-65. DOI: 10.1056/NEJMoa061292. View

Vo M, Lee H, Kim J, Hoang M, Choi N, Rhee J . Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity. Oncotarget. 2015; 6(32):33781-90. PMC: 4741802. DOI: 10.18632/oncotarget.5281. View

Siena S, Van Cutsem E, Li M, Jungnelius U, Romano A, Beck R . Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer. PLoS One. 2013; 8(11):e62264. PMC: 3823943. DOI: 10.1371/journal.pone.0062264. View

Reid D . Dendritic cells and immunotherapy for malignant disease. Br J Haematol. 2001; 112(4):874-87. DOI: 10.1046/j.1365-2141.2001.02626.x. View

Choi N, Lee H, Jung S, Hong C, Vo M, Hoang M . Generation of potent dendritic cells with improved migration ability through p-cofilin and sarco/endoplasmic reticulum Ca(2+) transport ATPase 2 regulation. Cytotherapy. 2015; 17(10):1421-33. DOI: 10.1016/j.jcyt.2015.06.002. View

Burgdorf S . Dendritic cell vaccination of patients with metastatic colorectal cancer. Dan Med Bull. 2010; 57(9):B4171. View

Shortman K, Lahoud M, Caminschi I . Improving vaccines by targeting antigens to dendritic cells. Exp Mol Med. 2009; 41(2):61-6. PMC: 2679330. DOI: 10.3858/emm.2009.41.2.008. View

Nguyen-Pham T, Jung S, Vo M, Thanh-Tran H, Lee Y, Lee H . Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in a Model of Murine Multiple Myeloma. J Immunother. 2015; 38(8):330-9. DOI: 10.1097/CJI.0000000000000097. View

Nair S, Boczkowski D, Morse M, Cumming R, Lyerly H, Gilboa E . Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol. 1998; 16(4):364-9. DOI: 10.1038/nbt0498-364. View

10.

Lee H, Choi N, Vo M, Hoang M, Lee Y, Lee J . Generation of multiple peptide cocktail-pulsed dendritic cells as a cancer vaccine. Methods Mol Biol. 2014; 1139:17-26. DOI: 10.1007/978-1-4939-0345-0_2. View

11.

Liu K, Wang C, Chen L, Cheng A, Lin D, Wu Y . Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Clin Cancer Res. 2004; 10(8):2645-51. DOI: 10.1158/1078-0432.ccr-03-0430. View

12.

Dredge K, Marriott J, MacDonald C, Man H, Chen R, Muller G . Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer. 2002; 87(10):1166-72. PMC: 2376196. DOI: 10.1038/sj.bjc.6600607. View

13.

Ferrajoli A, Lee B, Schlette E, OBrien S, Gao H, Wen S . Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008; 111(11):5291-7. PMC: 4082321. DOI: 10.1182/blood-2007-12-130120. View

14.

Hoang M, Jung S, Lee H, Lee Y, Nguyen-Pham T, Choi N . Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic. Chonnam Med J. 2015; 51(1):1-7. PMC: 4406989. DOI: 10.4068/cmj.2015.51.1.1. View

15.

Hong C, Lee H, Choi N, Jung S, Vo M, Hoang M . Sarcoplasmic reticulum Ca(2+) ATPase 2 (SERCA2) reduces the migratory capacity of CCL21-treated monocyte-derived dendritic cells. Exp Mol Med. 2016; 48(8):e253. PMC: 5007641. DOI: 10.1038/emm.2016.69. View

16.

Jack A, Aydin N, Montenegro G, Alam K, Wallack M . A novel dendritic cell-based cancer vaccine produces promising results in a syngenic CC-36 murine colon adenocarcinoma model. J Surg Res. 2007; 139(2):164-9. DOI: 10.1016/j.jss.2006.09.024. View

17.

Vermorken J, Claessen A, van Tinteren H, Gall H, Ezinga R, Meijer S . Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet. 1999; 353(9150):345-50. DOI: 10.1016/S0140-6736(98)07186-4. View

18.

Yamaguchi S, Tatsumi T, Takehara T, Sakamori R, Uemura A, Mizushima T . Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines. Cancer. 2007; 110(7):1469-77. DOI: 10.1002/cncr.22958. View

19.

Hernandez-Ilizaliturri F, Reddy N, Holkova B, Ottman E, Czuczman M . Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res. 2005; 11(16):5984-92. DOI: 10.1158/1078-0432.CCR-05-0577. View

20.

Hoang M, Lee H, Lee H, Jung S, Choi N, Vo M . Branched Polyethylenimine-Superparamagnetic Iron Oxide Nanoparticles (bPEI-SPIONs) Improve the Immunogenicity of Tumor Antigens and Enhance Th1 Polarization of Dendritic Cells. J Immunol Res. 2015; 2015:706379. PMC: 4499411. DOI: 10.1155/2015/706379. View